Mantle cell lymphoma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(13 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{ Mantle cell lymphoma }}
{{Mantle cell lymphoma }}
 
{{CMG}}; {{AE}} {{Akram}}


{{CMG}}; {{AE}} {{AS}}
==Overview==
==Overview==
Mantle cell lymphoma is a rare disease that tends to affect elderly patients > 60 years. In 2015, the incidence of mantle cell lymphoma was estimated to be 1.3 cases per 100,000 individuals in the United States. The prevalence of mantle cell lymphoma is estimated to be 5 cases per 100,000 individuals in the United States. Males are more commonly affected with mantle cell lymphoma than females. The male to female ratio is approximately 4 to 1.  
Mantle cell lymphoma accounts for 4–8% of all adult [[Non-Hodgkin lymphoma|non-Hodgkin lymphoma]] (NHL). It has an [[incidence]] of approximately 1-2 per 100,000 individuals worldwide. The male to female ratio is approximately 4 to 1 and the median age is about 60 years.
 
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
In 2015, the incidence of mantle cell lymphoma was estimated to be 1.3 cases per 100,000 individuals in the United States.
* The annual [[incidence]] of mantle cell lymphoma has increased during recent decades to 1–2 per 100,000 individuals worldwide.<ref>{{Cite journal
===Prevalence===
| author = [[M. Dreyling]], [[C. Geisler]], [[O. Hermine]], [[H. C. Kluin-Nelemans]], [[S. Le Gouill]], [[S. Rule]], [[O. Shpilberg]], [[J. Walewski]] & [[M. Ladetto]]
* The prevalence of mantle cell lymphoma is estimated to be 5 cases per 100,000 individuals in the United States.  
| title = Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
* The prevalence seems to be somewhat higher in Europe.
| journal = [[Annals of oncology : official journal of the European Society for Medical Oncology]]
===Age===  
| volume = 25 Suppl 3
Mantle cell lymphoma tends to affect elderly patients > 60 years.<ref name=”seer”>National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref>
| pages = iii83–iii92
| year = 2014
| month = September
| doi = 10.1093/annonc/mdu264
| pmid = 25210087
}}</ref>
   
===Age===
*The median age at [[diagnosis]] for mantle cell lymphoma is about 60 years.<ref>{{Cite journal
| author = [[Arati A. Inamdar]], [[Andre Goy]], [[Nehad M. Ayoub]], [[Christen Attia]], [[Lucia Oton]], [[Varun Taruvai]], [[Mark Costales]], [[Yu-Ting Lin]], [[Andrew Pecora]] & [[K. Stephen Suh]]
| title = Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
| journal = [[Oncotarget]]
| volume = 7
| issue = 30
| pages = 48692–48731
| year = 2016
| month = July
| doi = 10.18632/oncotarget.8961
| pmid = 27119356
}}</ref>
 
===Race===
*Mantle cell lymphoma tends to affect Caucasians more than African-Americans.<ref>{{Cite journal
| author = [[Yuhong Zhou]], [[Haijun Wang]], [[Wenjing Fang]], [[Jorge E. Romaguer]], [[Yanxia Zhang]], [[Kay B. Delasalle]], [[Larry Kwak]], [[Qing Yi]], [[Xianglin L. Du]] & [[Michael Wang]]
| title = Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
| journal = [[Cancer]]
| volume = 113
| issue = 4
| pages = 791–798
| year = 2008
| month = August
| doi = 10.1002/cncr.23608
| pmid = 18615506
}}</ref>
===Gender===
===Gender===
Males are more commonly affected with mantle cell lymphoma than females. The male to female ratio is approximately 4 to 1.
*[[Males]] are more commonly affected by mantle cell lymphoma than [[females]]. The male to female ratio is approximately 4 to 1.<ref>{{Cite journal
| author = [[Arati A. Inamdar]], [[Andre Goy]], [[Nehad M. Ayoub]], [[Christen Attia]], [[Lucia Oton]], [[Varun Taruvai]], [[Mark Costales]], [[Yu-Ting Lin]], [[Andrew Pecora]] & [[K. Stephen Suh]]
| title = Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
| journal = [[Oncotarget]]
| volume = 7
| issue = 30
| pages = 48692–48731
| year = 2016
| month = July
| doi = 10.18632/oncotarget.8961
| pmid = 27119356
}}</ref>


==References==
==References==
Line 27: Line 73:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 19:54, 7 January 2019

Mantle cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mantle cell lymphoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma epidemiology and demographics

on Mantle cell lymphoma epidemiology and demographics

Mantle cell lymphoma epidemiology and demographics in the news

Blogs on Mantle cell lymphoma epidemiology and demographics

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

Overview

Mantle cell lymphoma accounts for 4–8% of all adult non-Hodgkin lymphoma (NHL). It has an incidence of approximately 1-2 per 100,000 individuals worldwide. The male to female ratio is approximately 4 to 1 and the median age is about 60 years.

Epidemiology and Demographics

Incidence

  • The annual incidence of mantle cell lymphoma has increased during recent decades to 1–2 per 100,000 individuals worldwide.[1]

Age

  • The median age at diagnosis for mantle cell lymphoma is about 60 years.[2]

Race

  • Mantle cell lymphoma tends to affect Caucasians more than African-Americans.[3]

Gender

  • Males are more commonly affected by mantle cell lymphoma than females. The male to female ratio is approximately 4 to 1.[4]

References

  1. ↑ M. Dreyling, C. Geisler, O. Hermine, H. C. Kluin-Nelemans, S. Le Gouill, S. Rule, O. Shpilberg, J. Walewski & M. Ladetto (2014). "Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of oncology : official journal of the European Society for Medical Oncology. 25 Suppl 3: iii83–iii92. doi:10.1093/annonc/mdu264. PMID 25210087. Unknown parameter |month= ignored (help)
  2. ↑ Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter |month= ignored (help)
  3. ↑ Yuhong Zhou, Haijun Wang, Wenjing Fang, Jorge E. Romaguer, Yanxia Zhang, Kay B. Delasalle, Larry Kwak, Qing Yi, Xianglin L. Du & Michael Wang (2008). "Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004". Cancer. 113 (4): 791–798. doi:10.1002/cncr.23608. PMID 18615506. Unknown parameter |month= ignored (help)
  4. ↑ Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter |month= ignored (help)

Template:Hematology

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Mantle_cell_lymphoma_epidemiology_and_demographics&oldid=1515274"